Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,455,267
  • Shares Outstanding, K 57,771
  • Annual Sales, $ 51,500 K
  • Annual Income, $ -197,610 K
  • 60-Month Beta 2.15
  • Price/Sales 46.59
  • Price/Cash Flow N/A
  • Price/Book 3.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.65
  • Number of Estimates 10
  • High Estimate -1.46
  • Low Estimate -1.96
  • Prior Year -1.73
  • Growth Rate Est. (year over year) +4.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.41 +15.70%
on 11/18/19
43.70 -6.25%
on 12/09/19
+3.47 (+9.25%)
since 11/11/19
3-Month
35.41 +15.70%
on 11/18/19
45.86 -10.66%
on 09/12/19
-4.04 (-8.98%)
since 09/11/19
52-Week
35.41 +15.70%
on 11/18/19
74.50 -45.01%
on 04/05/19
-4.74 (-10.37%)
since 12/11/18

Most Recent Stories

More News
Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 40.97 (-3.60%)
Watch for Ultragenyx Pharm to Potentially Pullback After Gaining 6.48% Yesterday

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $41.31 to a high of $42.58. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high...

RARE : 40.97 (-3.60%)
Ultragenyx Pharm Shares Down 31.1% Since SmarTrend's Sell Call (RARE)

SmarTrend identified a Downtrend for Ultragenyx Pharm (NASDAQ:RARE) on July 9th, 2019 at $56.48. In approximately 5 months, Ultragenyx Pharm has returned 31.11% as of today's recent price of $38.91.

RARE : 40.97 (-3.60%)
Ultragenyx Pharm Rises 1.90% on Heavy Volume: Watch For Potential Pullback

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $38.15 to a high of $39.74. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high...

RARE : 40.97 (-3.60%)
Ultragenyx to Present at Piper Jaffray 31st Annual Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp,...

RARE : 40.97 (-3.60%)
Ultragenyx to Present at Upcoming Investor Conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced upcoming presentations...

RARE : 40.97 (-3.60%)
Look for Shares of Ultragenyx Pharm to Potentially Rebound after Yesterday's 4.32% Sell Off

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $37.85 to a high of $40.08. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of...

RARE : 40.97 (-3.60%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

BAYRY : 19.2300 (+0.52%)
AVEO : 0.71 (-1.94%)
RARE : 40.97 (-3.60%)
ASLN : 2.10 (-7.49%)
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -14.62% and -9.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RARE : 40.97 (-3.60%)
Ultragenyx: 3Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $113 million in its third quarter.

RARE : 40.97 (-3.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 43.54
1st Resistance Point 43.02
Last Price 40.97
1st Support Level 41.50
2nd Support Level 40.50

See More

52-Week High 74.50
Fibonacci 61.8% 59.57
Fibonacci 50% 54.96
Fibonacci 38.2% 50.34
Last Price 40.97
52-Week Low 35.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar